These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 565382)

  • 1. The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins.
    Nydegger UE; Fearon DT; Austen KF
    J Immunol; 1978 Apr; 120(4):1404-8. PubMed ID: 565382
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new haemolytic assay for the second component of complement (C2) in human serum.
    Naish PF; Barratt J; Collins C
    Clin Exp Immunol; 1976 Sep; 25(3):487-9. PubMed ID: 963910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
    Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
    J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 7. [Genetic deficiency of complement (author's transl)].
    Hauptmann G
    Nouv Presse Med; 1978 Nov; 7(38):3443-7. PubMed ID: 310996
    [No Abstract]   [Full Text] [Related]  

  • 8. Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement.
    Knutzen Steuer KL; Sloan LB; Oglesby TJ; Farries TC; Nickells MW; Densen P; Harley JB; Atkinson JP
    J Immunol; 1989 Oct; 143(7):2256-61. PubMed ID: 2506280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
    Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
    Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the alternative complement pathway in systemic lupus erythematosus.
    Wilson MR; Arroyave CM; Nakamura RM; Vaughan JH; Tan EM
    Clin Exp Immunol; 1976 Oct; 26(1):11-20. PubMed ID: 826360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the classical and alternative complement pathways in chemotaxis of human C2 deficiency (author's transl)].
    Pham Huu T; Buriot D; Griscelli C
    Ann Immunol (Paris); 1980; 131C(1):69-77. PubMed ID: 7396417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.
    Lachmann PJ; Halbwachs L
    Clin Exp Immunol; 1975 Jul; 21(1):109-14. PubMed ID: 52423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of histamine on monocyte complement production. II. Modulation of protein secretion, degradation and synthesis.
    Lappin D; Moseley HL; Whaley K
    Clin Exp Immunol; 1980 Dec; 42(3):515-22. PubMed ID: 7011615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of a low molecular weight complement inhibitor present in normal human serum.
    Baker PJ; Osofsky SG
    Clin Exp Immunol; 1981 Mar; 43(3):549-56. PubMed ID: 6912799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Participation of an early component of complement and Hageman factor in C3 destruction by zymosan.
    Gigli I; Koethe S; Austen KF
    Clin Immunol Immunopathol; 1975 Jul; 4(2):189-98. PubMed ID: 1170051
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):7-10. PubMed ID: 6778918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hereditary complement deficiencies].
    Fischer E
    Hautarzt; 1982 Feb; 33(2):65-72. PubMed ID: 6281215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.